RxDoctor Payments Data

Allen Hsieh, MD

Cardiovascular Disease · Morristown, NJNPI 1912992769

Payments from drug & device makers

$2,072in general payments, 2019–2025

Across 130 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$412
  • Amgen$317
  • Sanofi-aventis U.S. LLC$174
  • Johnson & Johnson$156
  • Boston Scientific$135
  • Merck$130
  • plus $748 from 17 others

What the payments were for

  • Food & beverage$2,072100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,072 in reported general payments places this provider in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$317,262
Medicare patients
1,016
Services billed
4,207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban592$750,736
EntrestoSacubitril/Valsartan209$274,775
XareltoRivaroxaban86$107,017
Repatha SureclickEvolocumab95$102,385
FarxigaDapagliflozin Propanediol63$59,271
MultaqDronedarone Hcl25$35,317
Praluent PenAlirocumab24$22,343
VascepaIcosapent Ethyl27$21,487
Valsartan297$14,184
BrilintaTicagrelor22$11,995
Icosapent Ethyl28$10,904
Ezetimibe408$10,569
Metoprolol Succinate648$10,311
Atorvastatin Calcium1,044$9,887
Pitavastatin Calcium25$6,669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$412$750,736592 claims
NovartisEntresto$77$274,775209 claims
Johnson & JohnsonXarelto$156$107,01786 claims
Sanofi-aventis U.S. LLCMultaq$174$35,31725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →